USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
      Featured
      Our Next Event
      Register for LSI USA ‘26
      500+ Investors & Strategics
      See LSI USA '26 Attendee List
      Events Overview
      • Our Summits
      • Who Attends
      • Why Present
      Upcoming Summits
      • LSI USA ‘26
      • LSI Asia ‘26
      • LSI Europe '26
      Past Summits
      • LSI USA ‘25
      • LSI Asia ‘25
      • LSI Europe ‘25
      • Archives
  • Insights
      Featured
      Just Launched
      Compass AI
      New Report
      Emerging Innovators Report
      Compass Al
      Emerging Innovators Report
      Market Data
      Custom Research
  • Magazine
      Featured
      February Edition
      Explore Latest Editions
      The Lens Magazine
      Start Your Subscription
      Magazine
      • The Lens Magazine
      • Explore the Newest Edition
      • Read Free Articles
  • Resources
      Featured
      Released Weekly
      The LSI Alumni Weekly Recap
      Just Released
      2025 LSI Alumni Funding Report
      Resources
      • Research Desk
      • Testimonials
      • Video Library
      • Photo Gallery
  • Company
      Featured
      Our Next Event
      Register for LSI USA '26
      Just Launched
      Compass AI
      Company
      • About Us
      • Our Team
      • Press
  • Contact Us
Contact Us
USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
  • Insights
  • Magazine
  • Resources
  • Company
Events Overview
  • Our Summits
  • Who Attends
  • Why Present
Upcoming Summits
  • LSI USA ‘26
  • LSI Asia ‘26
  • LSI Europe ‘26
Past Summits
  • LSI USA ‘25
  • LSI Asia ‘25
  • LSI Europe ‘25
  • Archives
Featured
Our Next Event
Register for LSI USA '26
350+ Investors & Strategics
See LSI USA '26 Attendee List
Compass Al
Emerging Innovators Report
Market Data
Custom Research
Featured
Just Launched
Compass AI
New Report
Emerging Innovators Report
Magazine
The Lens Magazine
Explore the Newest Edition
Read Free Articles
Featured
February Edition
Explore Latest Editions
The Lens Magazine
Start Your Subscription
Resources
Research Desk
Testimonials
Video Library
Photo Gallery
Featured
Released Weekly
The LSI Alumni Weekly Recap
Just Released
2025 LSI Alumni Funding Report
Company
About Us
Our Team
Press
Featured
Our Next Event
Register for LSI USA '26
Just Launched
Compass AI
Join our Next Event
LSI USA ‘26, March 16-20, 2026
Waldorf Astoria, Monarch Beach
Register Today
Compass AI
The medtech-specific AI
research platform by LSI
Demo Compass AI
The Lens Magazine
The Lens Medtech
Magazine is LSI's most
curated industry coverage.
  1. Video Library
  2. Spilling the Tea: What Really Happens in Device Deals | LSI USA '23

Spilling the Tea: What Really Happens in Device Deals | LSI USA '23

This extraordinary and unfiltered panel sheds light on the behind-the-scenes negotiations and stories involved in the process of medical device deals.
Share social-facebook social-x social-linkedin
Speakers
Brent Reinke
Brent Reinke
Shareholder, Stradling
Erich Wolff
Erich Wolff
SVP, Corporate Development & Strategy, BD
Chris Cleary
Chris Cleary
Vice President Corporate Development, Medtronic
Rakesh J. Mehta
Rakesh J. Mehta
Partner, Centerview Partners
Bio Bio
View Video Transcript
lsi logo
Contact Us

Upcoming Events

LSI USA ‘26
LSI USA ‘26
March 16-20, 2026
Dana Point, CA
LSI ASIA ‘26
LSI ASIA ‘26
June 30 - July 2, 2026
Singapore
LSI EUROPE ‘26
LSI EUROPE ‘26
Sept 28 - Oct 1, 2026
Barcelona

More From LSI

  • Attend an Event
  • Sponsor an Event
  • Compass, by LSI
  • The Lens, Magazine by LSI

Resources

  • Research Desk
  • Photo Gallery
  • Video Library
  • Testimonials
  • About Us

17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647

714-847-3540

© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy

Request Info
close
STEP 1
close-icon
The Lens - Complimentary Issue
close
close

Subscription Includes

Request Info

Global Medtech Market Analysis & Projections (MAP), 2021-2031
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf report

The Global Medtech Market Analysis and Projections (MAP) provides global market forecasts (2021 – ’31), share-by-supplier data, and analyst insights on 23 major device markets (e.g., Cardiovascular, Orthopedics, Neurovascular, In-Vitro Diagnostics) and 200+ technology subsegments. Understand major market trends and projections across the medtech industry with what medtech strategics and consulting firms have referred to as their “gold standard” for device market sizing data.

Global Surgical Procedure Volumes Dashboard, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Global Surgical Procedure Volumes database is the single source of truth for understanding diagnostic and therapeutic procedure volumes on a global scale. With coverage on 37 countries, including the United States, Europe’s Big Five, China, India, Japan and more for 12 major procedure markets (Cardio, Ortho, General Surgery, Radiosurgery, Neuro, OB/GYN and more), this fully interactive database is designed to facilitate one-to-one analyses of procedures, countries, and regions. Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

United States Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United States Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United States. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Aesthetics, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Aesthetics Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Aesthetics Procedures Database covers major aesthetic procedures, including: Biopsies, Punch Biopsies, Shave Biopsies, Incisional Biopsies, Lesion Removal Procedures, Curettage, electrocautery, and electrocoagulation lesion destruction, Photodestruction, Cryotherapy-based lesion destruction, Lesion Removal Procedures: Traditional and Other, Abdominoplasty, Blepharoplasty, Breast Augmentation, Breast Lift, Breast Reduction, Buttock Augmentation, Buttock Lift, Cheek Implants, Chin Augmentation, Facelift, Forehead Lift, Gynecomastia Treatment, Hair Transplantation, Lip Augmentation, Liposuction, Lower Body Lift, Otoplasty, Rhinoplasty, Thigh Lift, Upper Arm Lift, Vaginal Rejuvenation, Surgeries for Cleft Palate and Lip, Surgeries for Burn Injuries.

Cardio, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Cardiothoracic and Interventional Cardiology Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Cardiothoracic and Interventional Cardiology Procedures Database covers major cardiothoracic and interventional cardiology procedures, including: CABG Surgeries Off-Pump CABG, On-Pump CABG, Valve Procedures Aortic Valve Replacements, Mitral Valve Replacements, MV Repairs, AV Repairs, PV Replacements, PV Repairs, TV Operations, Percutaneous Valvuloplasties, Percutaneous Valve Replacements, CHD Surgeries Ventricular Septal Defect Closures, Patent Ductus Arteriosus Repairs, Atrial Septal Defect Closures, Repair of Tetralogy of Fallot, Arterial Shunts Surgeries, Atrioventricular Septal Defect Repairs, Transposition of Great Artery Procedures, Anomalous Pulmonary Venous Return Repairs, Other Congenital Heart Disease Surgeries, Other Cardiothoracic Surgeries Aortic Aneurysm Procedures, Other Cardiothoracic Surgeries, Diagnostic and Therapeutic Catheterizations, Stand-Alone Diagnostic Cardiac Catheterizations, Percutaneous Coronary Interventions, Coronary Interventions Radial Approach, Coronary Interventions Femoral Approach, Heart Rhythm Procedures Conventional Pacemaker Procedures, ICD Procedures, Cardiac Resynchronization Device Procedures, Combined Defib/Resynch Device Procedures, Cardiac Ablations.

ENT, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ear, Nose, and Throat Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ear, Nose, and Throat Surgical Procedures Database covers major ear, nose, and throat procedures, including: Tonsillectomies, Operations on the Ear, FESS, Tracheostomies, Thyroidectomies & Parathyroidectomies, Stand-Alone Adenoidectomies, Tongue Operations, Laryngeal Operations, Pharyngeal Operations, Radical Neck Dissection.

General, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The General Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The General Surgeries Procedures Database covers major general surgical procedures, including: Cholecystectomies Laparoscopic Cholecystectomies, Open Cholecystectomies, Appendectomies, Laparoscopic Appendectomies, Open Appendectomies, Herniorrhaphies Laparoscopic Herniorrhaphies, Open Herniorrhaphies, Bariatric Surgeries Laparoscopic Bariatric, Open Bariatric, Selected Other Endoscopic General & Colorectal Procedures Esophageal (Other Endoscopic), Stomach & Intestinal (Other Endoscopic), Colorectal (Other Endoscopic), Liver (Other Endoscopic), Gallbladder & Biliary (Other Endoscopic), Pancreatic (Other Endoscopic), Other (Other Endoscopic), Other Surgeries Esophageal (Other General, non-Endoscopic), Stomach & Intestinal (Other General, non-Endoscopic), Colorectal (Other General, non-Endoscopic), Liver (Other General, non-Endoscopic), Gallbladder & Biliary (Other General, non-Endoscopic), Pancreatic (Other General, non-Endoscopic), Other (Other General, non-Endoscopic).

Neuro, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Neurosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Neurosurgery Procedures Database covers major neurosurgical procedures, including: Surgeries for Traumatic Brain Injuries, Ventricular & Shunt Surgeries, New Shunt Placements, Revision Shunt Surgeries, Endoscopic Third Ventriculostomies, Diagnostic Ventricular Endoscopies, Vascular Lesion Procedures, Vascular Lesion Surgeries, Vascular Lesion Coil Procedures, Pituitary Tumor Surgeries, Open Pituitary Tumor Surgeries, Endoscopic Pituitary Tumor Surgeries, Intracranial Tumor Surgeries, Open Intracranial Tumor Surgeries, Endoscopic Intracranial Tumor Surgeries, Cranioplasties, Intracranial Neurostimulation and Peripheral Nerve Procedures, Intracranial Neurostimulator Implant Procedures, Peripheral Nerve Neurostimulation Procedures, Other Peripheral Nerve Procedures.

OB/GYN, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Obstetric and Gynecological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Obstetric and Gynecological Surgical Procedures Database covers major obstetric and gynecological procedures, including: Obstetrical Surgeries Cesarean Sections, Destructive Operations, Episiotomies, Other Obstetrical Surgeries, Gynecological Surgeries Colposcopies, Hysterectomies, Salpingo-Oophorectomies & Oophorectomies, Colposcopies, Salpingo-Oophorectomies & Oophorectomies, Hysterectomies, Total Hysterectomies, Subtotal Hysterectomies, Vaginal Hysterectomies, Breast Cancer Surgeries, Breast Reconstruction Surgeries, Breast-Conserving Surgeries, and Mastectomies, among other surgeries.

Ophthalmology, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ophthalmological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ophthalmological Surgical Procedures Database covers major ophthalmological procedures, including: Cataract Surgeries, Phacoemulsification Surgeries, ICCE Surgeries, ECCE Surgeries, MSICS Surgeries, Refractive Surgeries.

Orthopedic, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Orthopedic Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Orthopedic Surgical Procedures Database covers major orthopedic procedures, including: Hip Arthroplasties Revision Hip Arthroplasties, Hip Resurfacing Procedures, Primary Hip Arthroplasties - Total Hip, Partial Hip, Knee Arthroplasties Revision Knee Arthroplasties, Primary Knee Arthroplasties - Partial Knee, Primary Knee Arthroplasties - Total Knee, Extremity Fractures Using Hardware Extremity Fractures Using Hardware - Upper Extremities, Extremity Fractures Using Hardware - Fractures of the Femoral Neck & Shaft, Extremity Fractures Using Hardware - Other Lower Extremity, Arthroscopies Knees (Arthroscopies), Shoulders (Arthroscopies), Ankles (Arthroscopies), Feet & Toes (Arthroscopies), Others (Arthroscopies), Other Joint Arthroplasties Finger & Hand, Wrist, Elbow, Shoulder, Ankle & Foot.

Peripheral Vascular, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Peripheral Vascular Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Peripheral Vascular Surgeries Procedures Database covers major peripheral vascular procedures, including: Arterial Procedures Thrombectomies & Thromboendarterectomies, Carotid Artery Thrombectomies, Upper Limb Artery Thrombectomies, Iliac Artery Thrombectomies, Renal Artery Thrombectomies, Lower Limb Artery Thrombectomies, Arterial Angioplasties, Carotid Artery Angioplasties, Upper Limb Artery Angioplasties, Iliac Artery Angioplasties, Renal Artery Angioplasties, Lower Limb Artery Angioplasties, Arterial Bypasses, Carotid Artery Bypasses, Upper Limb Artery Bypasses, Iliac Artery Bypasses, Renal Artery Bypasses, Aortofemoral and Aortobifemoral Bypasses, Femoropopliteal Bypasses, Femorotibeal Bypasses, Other Lower Limb Bypasses, Venous Procedures Head, Neck, & Upper Limb Thrombectomies & Thromboendarterectomies of Dialysis Access Venous Segments, Thrombectomies & Thromboendarectomies of Other Upper Limb Veins, Angioplasties of Dialysis Access Venous Segments, Angioplasties of Head, Neck and Other Upper Limb Veins, Lower Limb Venous Procedures Removals of the Saphenous Vein, Removals of Other Veins of the Lower Limbs.

Spine, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spine Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Spine Surgical Procedures Database covers major spine procedures, including: Cervical Spine Surgeries Cervical Spine Decompressions, Cervical Spine Discectomies, Cervical Spine Fusions, Cervical Spine Disc Replacements, Thoracic and Deformity Procedures Thoracic Spine Decompressions, Thoracic Spine Discectomies, Thoracic Spine Fusions, Instrumented Procedures for Deformities, Lumbar Procedures Lumbar Spine Decompressions, Lumbar Spine Discectomies, Lumbar Spine Fusions, Insertion of Lumbar Interspinous Process Spacer, Lumbar Spine Disc Replacements, Vertebroplasties & Kyphoplasties Vertebroplasties, Kyphoplasties, Other Spine Surgeries.

SRS, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Stereotactic Radiosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Stereotactic Radiosurgery Procedures Database covers major stereotactic radiosurgery procedures, including: Intracranial SRS Procedures, Extracranial SRS Procedures, Extracranial Spine Procedures, Extracranial Lung Procedures, Other Extracranial Procedures.

Urological, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Urological Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Urological Surgeries Procedures Database covers major urological procedures, including: Kidney Stone Procedures Extra Corporeal Shock Wave Lithotripsy, Percutaneous Nephro Lithotripsy, Ureteroscopies, Open Kidney Stone Procedures, BPH Procedures Transurethral Prostatectomies, Other BPH Surgeries, Prostatectomies, Nephrectomies Partial Nephrectomies, Radical Nephrectomies, Bladder Procedures Therapeutic Endoscopies, Diagnostic Endoscopies, Urethral Catheterizations of Bladder.

Global Markets for Hip Replacement Implants, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for hip replacement implants. The market for hip replacement implants includes all prosthetic devices used to replace damaged sections of the hip joint, including those used in total and semi/hemi replacement procedures. This market snapshot is intended to provide a high-level overview of the global market for hip replacement implants, with key insights into: Procedure volumes from 2022 to 2028, Market forecasts from 2022 to 2028, Competitive landscape analysis of major competitors, Insights into key market events for strategics and startups. Companies covered in this report include: B. Braun, DePuy Synthes, DJO Global, Exactech, Johnson & Johnson, Medacta, MicroPort Scientific, Ortho Development, OSSIS, SERF SAS, Smith+Nephew, Symbios Orthopedie, Total Joint Orthopedics, Zimmer Biomet.

Global Markets for Peripheral Vascular Guidewires, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Atherectomy Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Electrosurgery, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Vascular Balloons & Vena Cava Filter, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for percutaneous transluminal angioplasty (PTA) balloons and inferior vena cava (IVC) filters. A PTA balloon is used in the treatment of peripheral artery disease (PAD) to open a narrowed or blocked artery. IVC filters are permanent or temporary devices to prevent the travel of thrombotic material to the lungs. These devices are frequently used in the management of patients with severe PAD. This market snapshot is intended to provide a high-level overview of the global market for PTA balloons and IVC filters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Acotec Scientific, Adient Medical, B. Braun, BD, Biotronik, Boston Scientific, Brosmed, Cagent Vascular, Cardinal Health, CONMED, Cook Medical, Concept Medical, Cordis, Covellus, Degania Medical, iVascular, Medtronic, Merit Medical, NextStep Medical, Nipro, OrbusNeich, Orchestra BioMed, Philips, Terumo, TriReme Medical.

Global Markets for Mechanical Heart Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Tissue Heart Valve Replacement, 2023-2028
Published:
2023
Next Update:
Q2 2030
Deliverables:
excel pdf

Description coming soon.

Global Markets for Transcatheter Mitral Valve Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Femoral Closure, 2023-2029
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for femoral closure devices. Femoral closure devices are used to achieve hemostasis of the hole in the artery that is created to perform catheter-based cardiovascular or endovascular procedures. This market snapshot is intended to provide a high-level overview of the global market for femoral closure devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Cardinal Health, Cardiva, Cordis, CyndRx, Endocor, Haemonetics, Morris Innovative, Rex Medical, Teleflex, Terumo, Transluminal Technologies, Vasorum, Vivasure Medical.

Global Markets for Tricuspid Valve Repair, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for tricuspid valve repair devices. Tricuspid valve repair is the preferred surgical approach for the treatment of degenerative tricuspid valve disease. The market is currently experiencing a renaissance with the introduction and development of transcatheter solutions for tricuspid valve repair and replacement. Devices covered within the scope of this analysis include tricuspid valve annuloplasty rings and transcatheter tricuspid valve repair devices. This market snapshot is intended to provide a high-level overview of the global market for tricuspid valve repair devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, CroiValve, Edwards Lifesciences, Innoventric, Medtronic, Mitral Holdco, Mitralix, NaviGate, OrbusNeich, TriCares, Venus Medtech.

Global Markets for Percutaneous Pulmonary Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for transcatheter pulmonary valve devices. Pulmonary valve replacement is performed primarily for the treatment of pulmonary valve stenosis, a relatively rare disease associated with congenital heart defects. Devices covered within the scope of this analysis include transcatheter pulmonary valve implants for valve repair and replacement. This market snapshot is intended to provide a high-level overview of the global market for transcatheter pulmonary valve devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Edwards Lifesciences, Medtronic, PolyVascular, Venus Medtech.

Global Markets for Coronary Angio Guidewires & Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for coronary angiography catheters and guidewires. These devices are essential to perform coronary angiography, a minimally invasive medical procedure used to visualize blood flow, identify blockages and narrowing of the coronary arteries. Devices covered within the scope of this analysis include coronary angiography catheters and coronary angiography guidewires. This market snapshot is intended to provide a high-level overview of the global market for coronary angiography catheters and guidewires, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AngioDynamics, B. Braun, Boston Scientific, Cardinal Health, Cook Medical, Cordis, Medtronic, Merit Medical, Philips, Teleflex, Terumo.

Global Markets for Oncology Ablation Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology ablation catheters. These devices are used as a therapeutic modality employing energy to selectively destroy cancerous tissue. Devices covered within the scope of this analysis include radiofrequency and microwave ablation electrodes, excluding cryoablation devices, which are covered in a separate report. The snapshot offers a high-level overview of the global market for oncology ablation catheters and guidewires, with key insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: AngioDynamics, Baylis, Boston Scientific, Canyon Medical, CAPS Medical, EDAP, Galvanize Therapeutics, Imagin Medical, Medtronic, Mermaid, Mirai Medical, Monteris, Sonablate, Stryker, TROD Medical, and US Medical Innovations.

Global Markets for ENT Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for endoscopic devices for ear, nose, and throat (ENT) surgery. These devices are used to examine and operate on the structures and tissues in the ear, nose, and throat. Devices covered within the scope of this analysis include ENT endoscopic surgical instruments, balloon sinus and dilation catheters, and rigid endoscopes and bronchoscopes. This market snapshot is intended to provide a high-level overview of the global market for ENT endoscopic surgery devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: 3NT Medical, Acclarent, Conmed, Endoluxe, Entellus Medical, Intuitive Surgical, Johnson & Johnson, KARL STORZ, Medtronic, Olympus, Pentax, Pristine Surgical, Richard Wolf, Smith & Nephew, Stryker, Tympany Medical.

Global Markets for Cell Delivery Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cell delivery catheters. These devices are primarily research-use devices for the delivery of cellular therapies for the treatment of chronic diseases, such as cardiovascular disease and cancer. Devices covered within the scope of this analysis include cell delivery catheters. This market snapshot is intended to provide a high-level overview of the global market for cell delivery catheters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: BioCardia, Biosense Webster, Boston Scientific, Cordis, Medtronic, Mercator MedSystems, TriSalus Life Sciences, TRI Medical.

Global Markets for Urology Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for urology and renal devices, focusing on treatments for six major conditions: End-stage renal disease (ESRD), Incontinence, Calculi (stones), Benign prostatic hyperplasia (BPH), Prostatitis, and Erectile dysfunction (ED). The devices covered within this analysis encompass a range of tools for diagnosis, treatment, and management, including urinary bags, foley catheters, catheter insertion kits, intermittent catheters, endourology devices, BPH ablation devices, lithotripsy devices, and artificial penis devices. The snapshot provides key insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: 3M, Applied Medical, Astratech, Balton, Baxter Healthcare, B. Braun, BD, Boston Scientific, Calyxo, Corinth Medtech, Coloplast, EndoMed, Flume Catheter Company, Hollister, ICU Medical, Karl Storz, Medline, Medtronic, Merit Medical, Nipro, Olympus, SonoMotion, Teleflex, and Urovision.

Global Markets for External Pain Pumps, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for external pain pumps. These devices are used to provide patients with consistent, long-lasting pain relief by delivering pain medication epidurally, intravenously, or subcutaneously. Devices covered within the scope of this analysis include external infusion pumps for pain management. This market snapshot is intended to provide a high-level overview of the global market for external pain pumps, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Avanos, B. Braun, BioQ Pharma, Epic Health, ICU Medical, InfuTronix, Medical Flow Systems, Medipacs, MicroPort, Smiths Medical, Teleflex.

Global Markets for Ureteral Access Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence delves into the global market for ureteral access devices, crucial components utilized alongside ureteroscopy or percutaneous nephrolithotomy procedures. These devices facilitate dilation and create a working channel for various urologic interventions. The snapshot aims to offer insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it provides a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Amecath, Applied Medical, BD, Boston Scientific, Cook Medical, Envaste, Johnson & Johnson, Mednova, Olympus, Richard Wolf, Rocamed, Teleflex, and Terumo.

Global Markets for Pelvic Floor Repair, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for pelvic floor repair mesh. These products are used during surgical procedures to repair prolapse and urinary incontinence. Devices covered within the scope of this analysis include pelvic floor repair/reconstruction mesh. This market snapshot is intended to provide a high-level overview of the global market for pelvic floor repair mesh, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: BD, Boston Scientific, Coloplast, Cook Medical, Ethicon, Johnson & Johnson.

Global Markets for Atrial Fibrillation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Neurovascular Devices Ischemic, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence analyzes the global market for devices used in the treatment of ischemic stroke, focusing on solutions designed to remove occlusions in blood vessels to prevent and treat this condition. The market snapshot offers insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Cerenovus, Ceretrieve, Cordis, InNeuroCo, Julier, Medtronic, MicroPort Scientific, Microvention, Penumbra, Phenox, Poseydon Medical, Route 92 Medical, Stryker, and Terumo.

Global Markets for Neuromodulation Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global neuromodulation market – a thriving market for managing and treating neurological diseases, chronic pain, and other chronic conditions. Types of neuromodulation, or neurostimulation, devices include implantable and transcutaneous devices, including wearable devices. This market snapshot is intended to provide a high-level overview of the global neuromodulation market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bionics, Alyve Medical, Axonics, Biotronik, Boston Scientific, EBT Medical, electroCore Medical, Inspire Medical, LivaNova, Medtronic, Neuromod Devices, Nevro.

Global Markets for Vertebroplasty Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vertebral augmentation products, which are crucial in treating vertebral compression fractures, often caused by osteoporosis or spinal tumors. Vertebroplasty and kyphoplasty are the primary surgical interventions, and the market includes products such as vertebroplasty and kyphoplasty cement, as well as delivery devices. The snapshot aims to provide a comprehensive overview of the global vertebral augmentation products market, with key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Halma, IZI Medical, Medtronic, Mendec, Merit Medical, RevBio, and Stryker.

Global Markets for TAVI/TAVR, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Drug Delivery, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Benign Prostation Hyperplasia Implants, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for implants for the treatment of symptomatic benign prostatic hypertrophy/hyperplasia (BPH). These implants are reversible solutions for men suffering from lower urinary tract symptoms (LUTS) caused by prostate enlargement. This market snapshot is intended to provide a high-level overview of the global BPH implants market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Butterly Medical, Endotherapeutics, Olympus, ProArc, ProVerum, Teleflex, Urotronic, ZenFlow.

Global Markets for Cryoablation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for cryoablation devices for non-cardiovascular applications. These devices are used to freeze and induce cellular damage and death for indications including cancer, dermatological conditions, peripheral vascular disease, and urological conditions. This market snapshot is intended to provide a high-level overview of the global cryoablation devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Boston Scientific, Brymill Cryogenics, Channel Medsystems, CooperSurgical, CPSI Biotech, CryoConcepts, CryoProbe, CryoSurgery, CSA Medical, Endocare, Endocision, Grand Cryo, Ictero Medical, KryoLife, Mectronic Medical, Sedivention, Siemens Healthineers, Varian Medical Systems, Wallach Surgical.

Global Markets for Diagnostic Electrophysiology Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for diagnostic electrophysiology catheters. These devices are used to measure and map electrical activity within the heart to identify aberrant electrical activity that causes arrhythmias. LSI projects that this market will remain in a high growth phase due to improving technology for the surgical treatment of cardiac arrhythmias and atrial fibrillation (AF). This market snapshot is intended to provide a high-level overview of the global diagnostic electrophysiology catheters market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AccuPulse, Acutus Medical, BD, Biosense Webster, Boston Scientific, CardioNXT, CoreMap, Johnson & Johnson, Kardium, Medtronic, MicroPort Scientific, Stereotaxis.

Global Markets for Hernia Repair, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence (LSI) provides an analysis of the global market for hernia mesh products for the surgical repair of hernias. The global market for hernia mesh products is projected to see moderate growth throughout the forecast period covered by the analysis. While the market has been negatively impacted by ongoing lawsuits associated with product complications, the next generation of products has helped the market to recover for one of the most performed abdominal surgeries. This market snapshot is intended to provide a high-level overview of the global market for hernia mesh products, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Allergan, Ariste Medical, BD, Cook Medical, Deep Blue Medical Advances, Ethicon, Exogenesis, Integra Lifesciences, Johnson & Johnson, LifeCell, Medtronic, Novus Scientific, Tarian Medical, TELA Bio, TISSIUM, W.L. Gore.

Global Markets for CRM Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac rhythm management (CRM) devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy devices (CRT-Ds). These implantable devices are used to restore the natural rhythm and function of the heart that can be impaired as a result of cardiac rhythm disorders and heart failure. This market snapshot is intended to provide a high-level overview of the global CRM devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AtaCor Medical, BioTrace Medical, Biotronik, Boston Scientific, Cairdac, Electroducer, FineHeart, Lepu Medical, LivaNova, Medico, Medtronic, Merit Medical, Microport Scientific, Osypka Medical, Pacetronix.

Global Markets for Neurovascular Devices Hemorrhagic, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for neurovascular devices for the treatment of hemorrhagic stroke. These solutions are used to treat intracerebral bleeds, ruptured aneurysms, and other neurovascular deformities that lead to the pooling of blood vessels that have ruptured inside and outside of the brain. This market snapshot is intended to provide a high-level overview of the global market for neurovascular devices for hemorrhagic stroke, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Acandis, Artio Medical, Endostream Medical, Medtronic, MicroPort Scientific, Microvention, Phenox, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo, Wallaby Medical.

Global Markets for Renal Denervation, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for renal denervation devices for the treatment of refractory hypertension (i.e., high blood pressure that does not respond to pharmaceuticals). The market for renal denervation devices includes radiofrequency and ultrasound catheters which are used to ablate the renal nerves. This market snapshot is intended to provide a high-level overview of the global market for renal denervation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Ablative Solutions, Brattea, Medtronic, Metavention, Otsuka Medical, ReCor Medical, SoniVie.

Global Markets for Upper+Lower Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence analyzes the global market for suture anchors used in upper and lower extremity repair and reconstruction procedures. Suture anchors play a critical role in securing soft tissue to bone, particularly for severe soft tissue tears. The market encompasses bioabsorbable, biocomposite, metallic, and PEEK suture anchors. The snapshot aims to offer insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Acumed, Acuitive Technologies, aevumed, Anika Therapeutics, Arthrex, ConMed, DePuy Synthes, Johnson & Johnson, Mitek, OSSIO, Paragon 28, Responsive Arthroscopy, Riverpoint Medical, Smith & Nephew, Stryker, and Zimmer Biomet.

Global Markets for Peripheral Stents, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for biliary and peripheral vascular stents. These devices are used to maintain and restore patency to anatomical ducts or vessels that have become obstructed due to the formation of plaque, narrowing of the natural lumen, or presence of benign and malignant growths. This market snapshot is intended to provide a high-level overview of the global peripheral vascular and biliary stents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, BD, Biotronik, Boston Scientific, Bryan Medical, Cardinal Health, Cook Medical, Cordis, Endo GI Medical, Hood Labs, Maquet, Medtronic, Merit Medical, MicroPort Scientific, Olympus, Q3 Medical, Zorion Medical.

Global Markets for Electromagnetic Navigation Systems, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for electromagnetic navigation systems for tracking, guiding, and positioning instruments during surgery. These systems provide surgeons and the surgical team with real-time information on the position and orientation of instruments used during open and minimally invasive surgeries. This market snapshot is intended to provide a high-level overview of the global electromagnetic navigation systems market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Brainlab, Collin Medical, Elucent Medical, Fiagon, Heal Force, Joimax, Karl Storz, Medtronic, Olympus, Stryker, Veran Medical Technologies.

Global Markets for GI Endoscopy, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot report from Life Science Intelligence provides an analysis of the global market for gastrointestinal (GI) endoscopic devices. These devices are used to visualize, diagnose, and surgically treat conditions of the GI tract. The market for GI endoscopic devices includes endoscopes and endoscopic instruments. This market snapshot is intended to provide a high-level overview of the global market for GI endoscopic devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Ambu, Applied Medical, Aqua Medical, Aspero Medical, B. Braun, Boston Scientific, ConMed, Endoluxe, Ethicon, Integra Lifesciences, Intuitive Surgical, IQ Endoscopes, Johnson & Johnson, Karl Storz, Medtronic, MiWendo Solutions, Olympus, Purple Surgical, Richard Wolf, Stryker, Teleflex.

Global Markets for Hemodialysis, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for hemodialysis solutions. Hemodialysis is an essential treatment for patients suffering from end-stage renal disease due to kidney failure. Hemodialysis systems, catheters, and dialyzers are components integral to hemodialysis treatment. This market snapshot is intended to provide a high-level overview of the global hemodialysis solutions market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Asahei Kasei, AngioDynamics, B. Braun, Baxter, Bellco, Byonyks, Diality, Fresenius, Hemoclean, Humacyte, Intermedt, Inspira Health, iRen-MEDICAL, Medivators, Merit Medical, NextKidney, Nikkiso, Nipro, Rockwell Medical, Telelfex, Terumo, Toray Medical, TVA Medical, Vantive.

Globals Markets for Cardiac Ablation, 2023-2028
Published:
Next Update:
Deliverables:

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac ablation devices, which are used for the treatment of arrhythmic heart conditions, such as atrial fibrillation. The market for cardiac ablations devices is projected to see strong growth throughout the forecast period covered by this analysis, driven by demographic trends and the adoption of new technologies for the treatment of new ablation technologies, such as Pulsed Field Ablation. Devices covered within the scope of this analysis include cardiac ablation catheters. This market snapshot is intended to provide a high-level overview of the global market for cardiac ablation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Adagio Medical, AtriAN Medical, AtriCure, Biosense Webster, Boston Scientific, Electrophysiology Frontiers, Field Medical, Galvanize Therapeutics, Healium Medical, Johnson & Johnson, Medtronic, Stereotaxis.

Global Markets for Atrial Septal Occlusion, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for atrial septal occlusion devices. These devices are used to close atrial septal defects (ASDs), an abnormal hole in the wall of the upper chambers of the heart that are present at birth. This market snapshot is intended to provide a high-level overview of the global ASD occlusion devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, atHeart Medical, Cardia, Hanyu Medical, Lifetech Scientific, Occlutech, W.L. Gore.

Global Markets for Aortic Grafts, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for aortic stent grafts for the treatment of aortic aneurysm. The market for aortic stent grafts includes open (surgical) and endovascular (transcatheter) aortic stent grafts used in the repair of abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). This market snapshot is intended to provide a high-level overview of the global market for aortic stent grafts, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Cook Medical, Endoron, Endospan, Lombard Medical, Medtronic, MicroPort Scientific, Taurus Vascular, Terumo, TripleMed, W.L. Gore.

Global Markets for Interventional Cardiology Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for interventional cardiology devices for the treatment of cardiovascular diseases such as heart failure or severe atherosclerosis. The market for interventional cardiology devices includes devices used to diagnose and treat diseases related to the coronary arteries. Devices included within the scope of this report include coronary stents, catheters, angioplasty balloons, guidewires, and intravascular ultrasound catheters. This market snapshot is intended to provide a high-level overview of the global market for interventional cardiology devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bifurcation Systems, B. Braun, BD, Boston Scientific, Cardinal Health, Cook Medical, Corflow Therapeutics, Fastwave Medical, Lemaitre Vascular, Medtronic, Merit Medical, MicroPort Scientific, NirvaMed, Philips, Teleflex, Terumo, Translumina.

Global Markets for Oncology Embolization, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology embolization agents, including radioembolization, chemoembolization, and particle embolization devices. These solutions are used to occlude blood vessels to lesions and tumors to derive the target of nutrients, enhance the effectiveness of the targeted delivery of pharmaceuticals, and trigger cell death. This market snapshot is intended to provide a high-level overview of the global oncology embolization agents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: ABK Biomedical, Arsenal Medical, Boston Scientific, Cook, Cordis/Cardinal Health, Instylla, Medtronic, Merit Medical, Ned Medical, Obsidio, SirTex Medical, Stryker, Terumo, Varian.

Global Markets for Vascular Access Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vascular access devices, which are essential for continuous and long-term access to the bloodstream for administering intravenous drugs and fluids. The market encompasses various types of devices, including peripherally inserted central catheters (PICC), midline catheters, central venous catheters (CVC), and implantable ports. The snapshot aims to provide a comprehensive overview of the global market for vascular access devices, offering key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Access Vascular, AngioDynamics, B. Braun, Baxter, Becton, Dickinson & Company (BD), Bluegrass Vascular, C.R. Bard, Cook Medical, ICU Medical, Medline, Smiths Medical, Teleflex, Terumo, Vygon, and Yushin Medical.

Global Markets for Rotator Cuff Repair Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for rotator cuff repair suture anchors for the treatment of rotator cuff injuries. The market for rotator cuff repair suture anchors includes anchors composed of biocompatible polymers and metals. This market snapshot is intended to provide a high-level overview of the global market for rotator cuff repair suture anchors, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Aevumed, Arthrex, Atreon Orthopedics, ConMed, DePuy Synthes, Embody, Inovedis, Smith & Nephew, Stryker, Tetrous, Wright Medical, Zimmer Biomet.

Global Markets for Electrical Stimulation Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Wearable Monitoring Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Low Complexity Medical Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Canada Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Canada Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Canada. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Germany Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Germany Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Germany. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

France Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The France Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for France. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

U.K. Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United Kingdom Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United Kingdom. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Italy Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Italy Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Italy. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Spain Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spain Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Spain. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Poland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Poland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Poland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Netherlands Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Netherlands Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Netherlands. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Belgium Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Belgium Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Belgium. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Sweden Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Sweden Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Sweden. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Switzerland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Switzerland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Switzerland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Denmark Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Denmark Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Denmark. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Finland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Finland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Finland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Norway Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Norway Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Norway. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

China Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The China Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for China. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

India Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The India Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for India. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Japan Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Japan Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Japan. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Korea Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Korea Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Korea. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Australia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Australia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Australia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Thailand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Thailand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Thailand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Malaysia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Malaysia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Malaysia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Singapore Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Singapore Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Singapore. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

New Zealand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The New Zealand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for New Zealand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Caribbean Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Caribbean Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Caribbean region. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Argentina Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Argentina Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Argentina. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Colombia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Colombia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Colombia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Chile Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Chile Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Chile. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Guatemala Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Guatemala Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Guatemala. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Dominican Republic Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Dominican Republic Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Dominican Republic. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Costa Rica Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Costa Rica Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Costa Rica. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Panama Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Panama Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Panama. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Mexico Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Mexico Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Mexico. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Brazil Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Brazil Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Brazil. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Turkey Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Turkey Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Turkey. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Russia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Russia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Russia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Africa Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Africa Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Africa. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.
Schedule Meeting
Request Info
close
Video Transcription
close

Transcription


Brent Reinke  0:07  


I, I do have to preface one thing is like I agreed to moderate this panel and then found out what they really wanted to do. So I think you'll enjoy it. Again Brent Reinke, shareholder with Straddling Dr. Carlson Roth. Those of you not familiar with the law firm, we've got 120 lawyers firm, wide 12 offices in five western states, I do corporate law. Actually, I work in our Westlake Village office, which is in between LA and Santa Barbara where Amgen is located and there's a lot of life science activity going on up there, which is really exciting. Before we get into the the panel discussion, at first, I was going to have to as a as a California native apologize to you guys, especially the ones that are from out of town about the weather we provide it, but it looks like there's some sun coming out. So I hope it stays that way. Because, frankly, we're getting a bit tired of all these atmospheric rivers as they call them. But based on the gist of what I think is going to be discussed on this panel that I got last week, I learned two things when we had about a 10 minute conversation. First, I was kind of the odd person out because these guys know each other really well. Which was was great to hear. And secondly, they have a lot of interesting stories that I think they're going to be able to tell. So even if we didn't have sunshine today, I think these guys will bring a little bit and probably a few smiles to your face based on the stories they have. There was an aspect of me that felt like almost had to do a disclaimer, and I was talking to Rak about this the typical one where the you hear on a TV station where they say the views and opinions of those about to speak are not necessarily those of me. We'll see if that's the case by the end of this. But I'm looking forward to the discussion, especially with the industry knowledge and experience that these guys have. So real quickly, not going to take a long time to do it. But I wanted to you know, more formally introduce the panelists, and I'll go from my immediate left. So it's Rak Mehta is the partner at Centerview Partners, which is an investment banking organization. And then we have Eric Wolf, who's the SVP of corporate development and strategy at BD. And then last but not least, who is apparently the one that thought of this panel and how to how to handle that is Chris Cleary is the VP of Corporate Development at Medtronic. So honestly, I feel like more of a monitor than a moderator on this one, just to make sure they don't go to outside the box. But I'm just going to turn it over to you guys and let you take it from here.


 


Rakesh Mehta  2:43  


All right. Well, before we get going, I'll just do a quick informal survey. How many people like the vest underneath the blazer? I just informal show of hands? How many people like that? I like it. Yeah, yeah. See, a lot of people like it. Fight me, Chris. He's been trying to get me to take this off all day, and it's not working. So look, 


 


Chris Cleary  3:02  


When you start sweating, you're gonna have an excuse.


 


Rakesh Mehta  3:04  


That might happen before this is over. So, you know, Chris called me a little while ago and just said, Hey, we're gonna do this panel, it can't be sort of the normal, happy horseshit. Let's let's try to just really be candid. Let's try to tell people what happens in between the deals like you know, people hear about the deal, it gets announced, but no one really knows the chemistry the back and forth that happened. So let's, let's just discuss that. And I'm like, Are you sure because I have a lot of tea to spill. I mean, I've been doing this for 25 years. I've known these guys for a couple of decades now. And I know a lot of words, and he was like, yeah, absolutely. You should absolutely talk about that. So I guess what I'll do, I'll start off by saying, the first thing you guys should know about these two is that they're not very nice people. So I you know, I say that, by the way, everything I say today is going to be true and verifiable. And by the way, whenever a banker tells you that you shouldn't dress that you should do your own homework, but we were it was early days of COVID. You know, everybody was scared. My wife's immune compromised. I just moved to Phoenix. I was trying to buy a house. And I called you know, the I was selling Companion and Eric was head of strategy at the diabetes business and Chris was doing whatever he does Medtronic and so they summoned me on a call we just put a bid on a house we've not gotten it and you know as you start these calls as one does, made some small talk and he says how you doing Rock and I'm like well, you know guys, I just you know my wife is really attached to his house and I put a bid in and you know, the broker used my bid, get somebody else to bid and took it away from me. And instead of showing some sympathy, these guys are like, wait, wait, wait, rock, wait, wait. So the seller got a bid. And then they took that bid, and ran it all over town and got a better price and left you at the altar by yourself? Is that what you're saying? And I'm like, yeah, guys, but my wife, he's like, Fuck you rock. You've done that to us seven times. So you're gonna get no empathy from these guys. So that's a starting story.


 


Erich Wolff  5:38  


It's great. Let me go next. All right, good. And there's a few people in this room or actually in this meeting, but this is a story about Chris and transatlantic transaction making. So we were, we were in, in London meeting with a an Asian company that had wildly lofty valuation targets in their mind, they wanted to sell their business for billions and billions of dollars, company was doing called sub $100 million of revenue at the time, there was jetlag, there was, I think, a little bit of food poisoning, perhaps. But we were, we're sitting across the table from each other. And we're gonna make a small, I'm looking at some folks in the room laughing. We're gonna make a small equity investment in their company, and then structure a way to ultimately acquire the entire the entire company. So we're sitting there, and Chris is taking it upon himself to be the lead negotiator. And he begins telling the other side who again, wants billions of dollars for this business, that pick a number, Listen, guys, pick a number, we're going to put in $50 million dollars. You tell us what valuation you want, we'll do it. You know, the, the number I care about the most is the is the acquisition number. So me and a couple of my colleagues are sitting next to Chris, and we're furiously scribbling math. And we're


 


Chris Cleary  7:02  


Gonna interrupt and say that while these guys are writing notes to themselves, like is Chris drunk. The other side is writing notes for themselves. And they're saying, Oh, my God, we're rich, we're rich.


 


Erich Wolff  7:11  


So we're trading this math. And we quickly get to the point where there's absolutely no possible rational reason for them to quote unquote, pick a number that we're going to agree to. So we had a call a timeout, pull Chris into a breakout room and explained to him that his math makes absolutely zero sense. We need to now go back in we need to do a complete Mia culpa, beg him and try to salvage the deal. So


 


Rakesh Mehta  7:42  


well see I said, they're not nice people.


 


Chris Cleary  7:45  


The title of this panel isn't the one time Eric was right.


 


So look, I'll tell a story that involves rock when I was pretty new, I started in 2014. And I think, what 15 for 12 that about right 2015 16 and a 15 began is 16. And we're buying 12 It's a heart valve company. And, you know, I get on the phone with him and his partner from JP Morgan at the time, Will Thiessen and, you know, we're we're having I'm being once again convinced that Rock's wife dynamic in Arizona, is true that there's another buyer and they put in a better bid and we have no chance and the other side prefers them quite a bit. You know, plus, I'm ugly. And you know, it's going on and on. And I start using movie lines. And I'm saying, Well, you know, go go go lunga lunga. And usually when I say a line from Caddyshack, I have to explain it and make people that are 30 year old associates watch the movie and come back but these guys were like sharp. They're like, Oh, wow, Caddyshack, reference, this could be really interesting. So we start building a relationship with each other around this deal in around arcane, like, you know, in the 80s and 90s, movie references, and we begin to have an actual relationship and, you know, it actually comes to pass. And what happens is, you're not nice people, you have a long collective elephant in memory. And I remember that they always said, there was another bid. And I had dinner with Andrew Clealand, who was the CEO of 12, like, I don't know, six months later, and I knew it was him. He didn't know is me. And I'm like at dinner, and I'm trying to get out of him without him knowing it's me, like who the other bidder was, and I can't do it. And then I formed a suspicion that the other bidder might have been another CEO. That was the owner of company we bought Heartware, and I'm thinking that can dunk God show how to be the other bidder. And I did the exact same thing to him. I set them up. I wanted to find out not only what his bid was the or if he was the bidder, but what his bid was in the only reason I wanted this was so I could go back to Rock and go there. I freaking knew they didn't have a better bit than we did. It was all bullshit lies what you told us. And you know, the point is, if you wonder like what we're doing in you know, when we go offline on deal negotiations and stuff like that it's this. It's absolutely senseless, where I'll silly things that we just need to know. Like Eric just you guys


 


Rakesh Mehta  10:25  


Are trusting your life's work in our hands basically. But look, I'll sort of keep building on this theme of these guys not being very nice. So you know, a lot of times you guys meet with them at Investor conferences, and, you know, medical conferences, and you meet with them. And, you know, a lot of founders call me CEOs call me go, you know, I met Chris Cleary, and boy, that guy's direct. He's straightforward. He's loved, loved talking to him. And I'm like, Look, he wants you to think that he's nice. He's not. Because let me let me let me take a step back. Okay? These guys are borderline psychopaths. Okay, and I'm gonna, I'm gonna go, I'm gonna go a little deep on this, because when these guys, what I'm about to say, is not verifiable. But it probably is true, which is when they were growing up, they were probably torturing puppies. Let me tell you where I'm going with this. Because they want to be nice to you when they meet you. Because if somebody tries to buy you, they want to get the call to say, Hey, are you interested in buying us? You know, Chris met with us, Eric met with us. They were really interested Rak, you gotta call them. And the reason they want you want to get that call, they're being nice to you at the conference, because you're not asking them for anything. But when you're ready to get them to buy you and you call them. That's when they get to crush your dreams, and say, No, we don't want to buy you. So it's, you know, now it's not cool. It's not cool to you know, kill puppies, so they kill dreams. That's what they do.


 


Erich Wolff  11:59  


Alright, that is a gross exaggeration. I will tell the counter story to that we there's folks in this room who actually worked on this transaction. We had, we had a Israeli organization that we found had absolutely core AI and machine learning capabilities based in based in Israel. And the the team all came out of the same unit of the Israeli military. They were very, very close knit group. And I hit number one objective was to acquire them and then keep them right. So our objective was, this is going to be an aqua hire, we care about the people we care about the team we care about. Maintaining that culture, in that organization, then having this is when I was at Medtronic having Medtronic build on those capabilities. And so the three founders and I met in Luxembourg, I flew over there was sort of this halfway point, I had other businesses there. And we sat down over a meal and literally hashed out all the aspects of the transaction, valuation, you know, continuity of the team, the vision for sort of where their their technology would fit into our broader ecosystem. And, and we ended up getting the deal done. And I remember this vividly, we went and did a town hall with Omar Issa, who is the CEO of Medtronic at the time, and he comes in, we welcome everybody to the to the family, and we have some time with some of the engineers and I'm in the car, headed back to the airport with Omar. And Omar says, Eric, I don't know if you noticed this, but half of the staff was barefoot, and there was a dog running around with a diaper on. So it was it was one of those moments, it's very, it was a very big sort of culture shock, I think to you know, legacy, you know, mega cap companies, but we ended up keeping that business, we kept everybody intact. When I left Medtronic, the CEO of that business actually took my job in the diabetes business, and Medtronic has continued to, to invest in pile on to that Israeli infrastructure. So I'm at least Nice.


 


Chris Cleary  14:17  


Yeah. And look, I, I've got a dog. And she's quite healthy. And it ties into this next story. So you know, we were we were an investor in a distributor for Mazhar surgical robotics, an Israeli company that did a spine robot for a long time. And, you know, we we knew we wanted to buy it, but we we couldn't make the math work, because the minute we did the distribution agreement, the valuation on the Israeli market ran away, it was very difficult to catch up to it and figure out how to make financial sense out of the acquisition. So you know, at some point, we we got to the point where we just had to figure out a way to do it. We ultimately ma Hold it saying, this is our life without a robot. This is our life with a robot. And the difference between the two lines is the deal model. And we figured out a way to make that work. And the pivotal component was that we realized that the CEO or her Domi, probably could sell it to another party and didn't just have to live distributing it through Medtronic forever. And that was the pivotal thing that made the model work. So you know, good for us, we cracked the model. And, you know, it's time to get serious and Ori needs a banker. So I'm at home petting my dog. And I'm like, I call rock because I don't want anything from him, I want to give something to him. I said, Corey, needs a banker, you should talk to him. So he does, and you know, all of a sudden, rocks got an engagement that you know, if he's good at his job he could get paid for. So we send a letter to Ori the traditional way, it's a public company, you have to do all this in writing, and says we want to buy you for I can't remember the prices, but it's a price per share. And I call rock afterwards. And he goes, Yeah, we had a board meeting. You know, all of a sudden, it's not like you and me. It's like we and you know you face.


 


I was interrupted my bike ride. Yeah,


 


we I was on a bike ride. We had a board meeting, and we don't have any response to your bid. And I just lose it. I'm like, that's not the way this works. When I say something, you have to say something. If when I say something, you don't say something, then the entire process breaks down. And there's no communication and without communication. Where are we really are we animals? So Rocks, like this, it but he won't give it up? Right? He's holding the investment banker line, we have no comment. So then I call up Ori and I'm yelling at them like God damn. You've got to give us a counterproposal. He's like Chris, Chris, don't be upset, what would be a good counter proposal, just tell me what to say. So just say number. Or he says a number you guys come down, I'm flying out to Minneapolis, I want to come to your place. And we'll work out the final numbers. So you know, I calm down. And my wife, me and my dog are there when Ori he gets there. And I'm not saying the story about the dog. Because what you said even though it was mean, spiteful, and unverifiable. But the dog was there. So where it comes in, I got a bottle of white wine. We go out in the balcony, in Ori I handed I didn't do it on purpose, but I handed him a huge red wine goblet. So he takes this bottle of white wine, he's a little bit nervous, you have to realize when you're doing a deal negotiation, you're dealing with like, Ori 15 years in this company, right? I mean, the price action, it mattered to him, mattered to all his employees, it mattered to the company's position in the Israeli exchange. You know, like everybody he knew, like this was a meaningful negotiation. Of course, you're nervous. He takes a bottle of wine, he pours about three quarters of it into this goblet. And he just starts drinking it and he's drinking one hand and petting my dog, Chloe with the other who's climbed up in his lap, and I'm looking at it going, Okay, I'm just gonna let him have that bottle. We go back and forth for no more than like three minutes. This was not a surgical procedure. It was like about this, about that about this elbow, and then put, you know, we arrived at whatever the heck it was right? 58 bucks, I gave her and he stands up. He goes, that was an enormous relief. And he drains the glass. Because Is there any more I got Sure. Empty the quarter of the bottle that slept. He drinks that it goes. So relieved, he puts the dog down, he walks up. He's like he came in walking all heavy, walked out, walk in real light. And I'm thinking you know what this is actually, this is what you live for. This is the actual good stuff that happens in deal negotiations, despite investment bankers best attempts to prevent it. Yeah. 


 


Erich Wolff  18:39  


Why did rock get paid?


 


Chris Cleary  18:41  


Like, where were you on that one?


 


Rakesh Mehta  18:43  


You know, on that deal. I never actually spent any time with the company. So they asked me to come out to Tel Aviv to you know, I understand the technology. And I fly in and I'm waiting at the airport. First of all, I tell them, I can only be there for a few hours because I have to be in Germany that night. So I fly and I'm thinking oh, they're gonna serve me a great, you know, I'm gonna have I love middle eastern food. They're gonna give me great food. So I get to the office around 1030 We're talking and I go, or he's like, Okay, should we break for lunch? I'm like, Yeah, let's see what you get. He goes sushi. I like I was hoping it'd be something else. But when I flew in, I was waiting for my ride. And all of a sudden, I see this guy just walking across the airport. And we look at each other. He goes, we both look at each other. Go What are you here for? We both know why we're there. We can't say it. We're just kind of like alright, well, I guess I'll see you took off and off we went. So it was a great transaction.


 


Chris Cleary  19:53  


From a bankers perspective. It was a dream job. 


 


Rakesh Mehta  19:58  


You want to moderate well


 


Brent Reinke  20:00  


Oh, you know, how do you? How do you moderate this? Well, I mean, obviously you guys have, you know, had experiences that were trying, but at the same time develop a really cordial relationship. Right?


 


Rakesh Mehta  20:15  


Well, in private, we're a lot more mean to each other than,


 


Brent Reinke  20:18  


well, you only when you're videotaping, and it'll be all over. So yeah, exactly. You really bash each other? Yes. Is


 


Chris Cleary  20:24  


there a way to end up the puppy thing?


 


Brent Reinke  20:27  


I mean, what, you know, what, what I know, in your careers, I mean, what does it really take to kind of maintain that, you know, kind of relationship? I mean, obviously, they're tough negotiations. There have to be, but how do you maintain the


 


Erich Wolff  20:41  


 Oh, well, first, I mean, so first of all, it's a small world, right? So all of us are going to bump into each other. And we'll continue to bump into each other. You know, rock. I've done multiple multiple deals with with Rocky, but I was


 


Rakesh Mehta  20:54  


counting between the three of us, we've probably done like, 15 deals together.


 


Erich Wolff  20:58  


 Yeah, we've done a lot of deals. And what I'll say is, you know, the negotiations, we have word fiduciary for our firms, we have an obligation to our shareholders to do you know, good transactions and smart transactions and strategic transactions. And, you know, Roc has the same responsibility for his clients. And so, you know, over the years, we've been, we've all become very, very close friends. But but, you know, Rock, he does his job. I mean, there, there are multiple times where, you know, you're looking for an edge on a deal, you're trying to figure out how competitive it really is, you know, back to the example that Chris gave, and, and so the relationships deeply matter. I think, from a strategic perspective, engaging and helping sellers understand what a future looks like, as part of the bigger organization matters. It's not just dollars, it's not just structure. It's, it's the relationship aspect of it. So I would not to get pick a corny sidebar, but I think the relationship element,


 


Rakesh Mehta  21:57  


but I think I think what's really important and deal making is, you know, sometimes the buyer is wrong. And it's Chris, you know, it's, it's my job to point that out to Chris and Eric, and it's their job to then convince people internally that they're wrong. And sometimes our client is wrong. And what what you really need is candor in that interaction, because if you know, you're you're not doing your client, you're doing your client a disservice if you're only parroting the client's point of view. You want to add Eric's absolutely right. That's my job is to advocate but sometimes, you know, we're not right. And when that happens, it's my job to turn around and go to my board and say, Look, this is a perspective they're bringing to the table. We may not agree with it, but it's a real issue. And let's figure out how to solve it. Right. And so that back and forth is was really, really important. That's well,


 


Brent Reinke  23:02  


I mean, you're you can take yourself out of the situation a little bit more than the people that are in it. Yeah, you have


 


Rakesh Mehta  23:08  


to have this passion and give back. Yeah, because look, I mean, you guys build companies, you guys are very, you know, immersed in doing something that will really changed the way medical practice happens. And you get passionate about that. And sometimes, it's not about your passion, it's about what makes makes the math work. And as you know, you need an intermediary who can be dispassionate about it, and that these guys serve the same role for their organizations.


 


Chris Cleary  23:37  


Yeah, you, you have to share your problems. And you have to listen to the other side's problems. And you have to, you know, you, you've got to tell the truth, right, you don't have you're not obliged to, like, tell people everything, but what you tell them has to be true. And you've got to earn credibility over the course of a relationship in it, sometimes you have to spend it with the other side, much more often as a strategic you have to spend it internally. And you've got to be able to, you know, because I'm, more often than not, in sympathetic, I sympathize with problems that the sellers have, that we can't reconcile internally. So I find myself having to like deal with a functional viewpoint that is at odds with what we've seen in diligence or at odds with what, you know, we hear from either a law firm or, you know, consultant or something like that. And you've you've got to go through that up and pounded down and you can't get a deal done.


 


Rakesh Mehta  24:37  


I'll give you a concrete example. Like we sold a company to Medtronic Hill Avenue, and we had a very candid back and forth about how we saw value versus how they saw value. And there was a component of the business that they just looked at it and said, Look, if you want us to we'll attach a milestone to it, but we're really not going to invest that much behind it. We just we're just telling you, we don't want to create false expectations. And that candor was really important, because then it allowed me to go back to my board and say, hey, look, you know, we could sugar, you know, we could put a milestone on, it will make us all feel better, but what's the value of it if they're really not going to invest behind it, and our board said, Well, then let's pull it out. And we managed it. And these guys were fully supportive, we managed to pull a piece of the business out, they actually were really constructive, they actually ended up investing in the company as well. And you know, at some point that might create another innovation engine for them. But you know, it was because we had this very candid discussion about what they valued versus what we valued that made the deal happen.


 


Brent Reinke  25:38  


Well, that's the other thing I've seen too. And maybe it's in smaller deals than that some of the deals you're talking about. But when you have that intermediary, where it's an investment bank, or somebody else that puts themselves in between the business executives, maybe the owners of the companies that have a real passion about what they do, and it starts to get personal. And yet we know that most of these deals, once they close, those are going to be an ongoing relationship. And you really don't want to damage the personal relationship, those two are going to need on a go forward basis, before they've even done a deal. And so I see that a real value in putting that person in between them kind of to take the heat and be whether it's the lawyer or the investment banker, whoever it might be to try to address what otherwise could get become a kind of a dicey situation


 


Erich Wolff  26:24  


in that it's also the job of corporate development, right. So within large strategic requires, there's business development in the businesses who are spending time with targets, they're looking at, you know, the capabilities of the leadership team, they're looking at the pipeline. And so, you know, not every deal that we work on has a banker necessarily involved. And so that is part of the job of corporate development, where we are the broker, if you will, between the business unit, who cares very, very deeply about the relationship on a go forward basis. And obviously, the targeted company. So it's a good, it's a good analogy,


 


Rakesh Mehta  27:01  


I think the one thing you guys as CEOs and founders should remember is that these guys are getting bombarded day and night by people calling them and saying you should buy us because we're the best thing since sliced bread. And so they have to bring a level of skepticism to the discussion. And, you know, you have to keep that in mind, because they're always getting pitch stuff that may or may not be real. And so they have to go through their own process to develop confidence in the idea and confidence in the market, and that there's no substitute for that other than execution and time. And so I would, you know, they want to listen, they want I mean, they want to create value for their companies, and it's there, it's in their interest to engage with you and learn more about you. But they also want to see execution over time. And, you know, you have developed that relationship, because deals don't happen, like, you know, like that you have to foster those discussions.


 


Brent Reinke  28:07  


Well, it's certainly better to have that vetting process happen, and bring out maybe some critical points that maybe the company the selling company has even thought about or hasn't addressed, then do the deal, and then have that come up later, because then you've got a problem, you know, particularly if you've got earnouts, or other things that are involved in that kind of transaction. So I you know, I I'm a big believer, as a lawyer of setting expectations with companies both buy and sell side about what the process is, and making sure people understand because it's, it's not easy to do you know, when especially when you're talking say lower middle market, you know, billion dollars in the last and revenue of running companies and trying to sell them at the same time, when you don't have people like this, you know, that are helping lead that kind of effort. It is not an easy process. And it's really critical. I've seen as an m&a lawyer to really make sure people understand what they're about to get themselves into. But I think it's important to bring up those issues. I mean, as a lawyer, I try to get our clients to rectify those issues before they go into a process. Because the process either gets slowed down, or it doesn't happen at all, if they start being brought up by the investment bankers or others, it's just a reason to renegotiate a deal. So we try to address them upfront, but I'm just evade, I think it's you guys are a great example of, of how relationships can help a process, you know, and you're, you're you're all doing your job. I mean, I think it's a, you know, it's something that is really a compliment when we represent a company. And after the deal closes. Let's say the the companies from out of the state of California deal out west coast transactions, and that that company that has done the acquisition doesn't have a law firm on the West Coast and they come back to us say, hey, we really respect what you did in the deal. You guys excuse Is the language are enough of an asshole in the process. But when it also showed us that you were going to vigorously represent your clients interest, and we respect that, and we respect what you did on the deal, and then you get engaged by basically the buyer to start representing the company they just acquired or any operations they have in the west coast. So, you know, I think it's, it's, it's, you know, relationships are key. And figuring out, the best way to build those relationships is is critical. And, and transactions like you guys are a great example of that,


 


Rakesh Mehta  30:32  


Chris, and Eric, what's what's the biggest misconception people have when they come talk to you guys about your organization's?


 


Chris Cleary  30:41  


Look, I think Medtronic is a pretty broad company, right? So you look at something you've developed that, you know, is overlapping a call point that Medtronic has in your like, you know, this is a better mousetrap, you should want to own it. And you know, that that's not the unfortunately, that's not the mission for Medtronic, right? The mission for Medtronic is we've got to provide a suitable shareholder return, to have the wherewithal to be able to be this big conglomerate holding company. And that means we need an optimal mix of, you know, like startup money that we spend, and then have to develop it on our p&l, or organic r&d development that's on our p&l in the use of our balance sheet for things that are closer to coming to market that can contribute to the p&l, right, we're managing a growth rate. And we've got to be able to grow at or above the market, at a level of profitability that doesn't make people sell our stock. And you got to think like that, right? So it's not you're managing when different when you see a promising technology, you don't automatically go, I want it, you have to appreciate it. And then you have to fit it into a capital allocation mindset. And it makes you way more deliberate than people would prefer that someone in my role be, you know, but you have to be because that's just the reality of it. I, you know, we we have to say yes, really deliberately in the context of the overall enterprise.


 


Rakesh Mehta  32:12  


Yeah, people come and tell me all the time, like Medtronic has to buy us a BD has to buy us and I'm telling them, No, they don't. There's nothing. There's nothing that they have to do. There's nothing, there's no sort of, they're a diversified portfolio that play in lots of different markets. And there's not one, you know, killer app that if they don't get is going to kill the company. And so you have to keep that even though you might have the best thing since sliced bread, you really have to convince the buyer universe, that you bring a value proposition that's additive to what the audience that they're playing to, which is their shareholders. And that how you tell that story? And how you convince people and the time that it takes I think that's the investment that you need to make.


 


Chris Cleary  32:57  


I'm calling the lightning round. Okay, two minutes, max. Best funniest deal story. No one cares about substance here. Make stuff up, Rak go. Cheese. Two minutes, there's been no preparation for this panel.


 


Rakesh Mehta  33:14  


Fun is still still on?


 


Erich Wolff  33:16  


Ticktick? I'll go first. Yeah. All right. So these are one of the biggest and most important aspects of our job. Is it naming the project name for the deal? All right, so good, what is the internal codename for the deal so that you can talk openly about the deal, but nobody around you knows what it is there's a lot of fights over the Advil adds a level of mystery to the deal. So there was a European based company that that we had been just pounding our head against the wall trying to acquire, we've tried stock deals, acid deals, structured deals, I mean, kind of you you name, you name it, we, we tried, we have this long history and cadence with the bankers on the other side, providing us guidance on valuation, then changing it guidance on transaction structure, then changing it. So I get to a frustration threshold that was off the charts and I went back through easily a year and a half of emails and meticulously crafted the timeline of all of the all of the lies essentially that I've been told over the past year and a half. And, and so then I invite Chris to this call, so he can firsthand experience the insanity of dealing with these parties. So we get on the call. And I begin I just lay in like listen guys, this has been a year and a half of ups and downs and sideways and left and right. And you know, back in April, you said this in May so that in June, you said that and all of a sudden the banker This is pre COVID So nobody was on video. You know, we're all huddled around you know, the tuck boxes, and he starts screaming at me at the top of his lungs, you, you who? You who, Eric, we don't do deals like this in Europe, yelling, interrupting me screaming yoo hoo. So we're literally just like, like, ball and mute, dying, laughing but also a little bit sober like this one, this guy's really upset. And so they ended up firing that bank because they obviously, you know, offended us and we're and in the deal was completely sideways hired another bank and to this day that deal will be project YooHoo


 


Chris Cleary  35:43  


alright, I know you need more time because you're processing Yeah, I'll go I'll go back to GE Capital. My favorite deal story is I'm buying Deutsche financial services on my own at closing. And it's a $6 billion deal. You know, the they own Bankers Trust in New York, we're meeting there. And they were literally like, we're done. Everything's done except the money hasn't hit the bank yet. And they've taken the Deutsche financial service signs down, they put up the GE Capital signs, they've had an open townhall, there's no turning back, except somebody in our Treasury Department thought they were sending $2 billion to Bankers Trust, but they pulled it out. So we're 4 billion short on the close, and I'm sitting there and there's no way that's like six o'clock, wires are shut down. There's no way to get the money there. And the guys kind of looking at me goes, you know, this is not acceptable. You can't do something like this. And you know, I'm a little younger, at the time, maybe a little more facile. I said, Look, you're a bank, right? Don't you guys lend money. So I wound up borrowing $4 billion from them at the Fed overnight fundraiser to close my own deal. And he's like, I can't believe I'm doing this. So you know, I drive home. It's Halloween. I drive home, I have a pretty nice Halloween, I wake up the next morning, Dennis cameraman, the CFO of GE Capital calls me up, he goes, Hey, did you just borrow $4 billion from beggars trust? He goes alright.


 


Rakesh Mehta  37:08  


all right, mines, mines, fewer dollars involved. So it's all related to a company that we sold to these guys called 12. Chris has alluded to it. Two things about that 12 was bought when they had six patients, and two of them were dead. And a number of people after that would call me and remind me of that and say, Hey, you sold that for half a billion. And I've got six patients, can you sell me for half a billion It's like, that's not what it was 400 million. But the during that deal. You know, I, you know, one of the nice things and the bad things about my job is that I can do it from anywhere, and we happen to be in Hawaii. And we were you know, it's they get started a little later than we do. So I would wake up really early in the morning at like four or five in the morning. And to not wake my family up, I just, you know, put on my headphones and go for a walk and do conference calls while I was walking. And I'm on the board call for that deal. And I just, you know, board calls at 5am. In the morning, I throw my headphones, and I start walking down the street. And I'm like, you know, I'm just gonna go walk, sit on the beach and do this call. And as I'm walking on the beach, all of a sudden, the stray dog starts chasing me. And so I'm on the board call and I'm sprinting as fast as I can down the street. And I get to the beach. And Andrew goes, rock when was that? There was a dog chasing me. He's like, are you serious? I'm like, yeah, like, okay, so then we The Board approved the deal?


 


Brent Reinke  39:00  


Well, well, I had a lot of dogs, a very limited number of responsibilities and trying to moderate this, this panel, but one of them. I was supposed to make sure we finished on time. So I'm looking at the clock and it's winding down. Do you guys have any last tidbits or insight?


 


Erich Wolff  39:16  


No, I just don't when we kick this off. Brent gets the three of us on the call. And he's walking through he takes charge and he walks us through. He's walking us through how he wants this session to go. So guys, you know, be really good to get insights from strategics trends you're seeing in the market. You know, we walked through this whole laundry list of you know, I've done this a lot of times moderated these panels. And he gets to the end of his list and goes are you guys comfortable with that? And Chris says no, no. In fact, I'm not gonna do any of that. We're not doing any of that. I'm very very uncomfortable with the list you just walked us through. This is how we're going to spend the time so the four of us this has been a real a real transcend


 


Rakesh Mehta  39:56  


despite me casting stones at these guys, they're complete pros and they're wonderful to work with and you can take anything they say to the bank so


 


Brent Reinke  40:08  


in this panel we kind of like


 


Erich Wolff  40:10  


we do we do thanks everybody All


 


Brent Reinke  40:12  


right thanks everyone guys


 

back Back to all attendees close
Rakesh J. Mehta

Rakesh J. Mehta

Partner, Centerview Partners

Rak Mehta is a founding member of the Medtech practice at Centerview Partners.  He has over 25 years of experience as a strategic advisor to life sciences management teams and boards across medical device, diagnostics, and tools, and biopharma companies.  Over the course of his career, Rak has engaged with clients on a broad range of complex strategic transactions, buy-side and sell-side mergers and acquistions, divestitures, debt and equity financings and partnerships.

  • Website website
back Back to all attendees close

Rakesh J. Mehta

Partner, Centerview Partners

Rak Mehta is a founding member of the Medtech practice at Centerview Partners.  He has over 25 years of experience as a strategic advisor to life sciences management teams and boards across medical device, diagnostics, and tools, and biopharma companies.  Over the course of his career, Rak has engaged with clients on a broad range of complex strategic transactions, buy-side and sell-side mergers and acquistions, divestitures, debt and equity financings and partnerships.

  • Website website
Rakesh J. Mehta